@curator

1 year ago

Article

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial - Nature Communications

Rating: 0.0

Likes: 1

Library: 1

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial - Nature Communications

NVSI-06-08 is a potential broad-spectrum recombinant COVID-19 vaccine that integrates the antigens from multiple SARS-CoV-2 strains into a single immunogen. Here, we evaluate the safety and immunogenicity of NVSI-06-08 as a heterologous booster dose in BBIBP-CorV recipients in a randomized, double-blind, controlled, phase 2 trial conducted in the United Arab Emirates (NCT05069129).

Rate This Post

Rate The Educational Value

Rate The Ease of Understanding and Presentation

Interesting or Boring? Rate the Entertainment Value

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial - Nature Communications

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge
for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge
for Humanity's Progress

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial - Nature Communications

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress